{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=valemetostat", "query": { "intervention": "valemetostat" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=valemetostat&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-09T02:05:33.993Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06244485", "title": "A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "Valemetostat tosylate", "type": "DRUG" }, { "name": "T-DXd", "type": "DRUG" }, { "name": "Dato-DXd", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2024-02-16", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-09-09T02:05:33.993Z", "location_count": 17, "location_summary": "Irvine, California • San Diego, California • Plantation, Florida + 13 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Plantation", "state": "Florida" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06244485" }, { "nct_id": "NCT03930953", "title": "A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "CC-99282", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Tafasitamab", "type": "DRUG" }, { "name": "Valemetostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 438, "start_date": "2019-05-20", "completion_date": "2028-02-09", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-09-09T02:05:33.993Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Tampa, Florida + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03930953" }, { "nct_id": "NCT04388852", "title": "DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Aggressive Variant Prostate Carcinoma", "Castration-Resistant Prostate Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Prostate Carcinoma", "Metastatic Urothelial Carcinoma", "Stage IV Prostate Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Valemetostat", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2020-08-20", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-09-09T02:05:33.993Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04388852" }, { "nct_id": "NCT06632977", "title": "Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Genetic testing", "type": "OTHER" }, { "name": "Valemetostat Tosylate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Bone scan", "type": "PROCEDURE" }, { "name": "FDG-Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "PSMA PET Scan", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Lutetium Lu 177 Vipivotide Tetraxetan", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 474, "start_date": "2025-02-06", "completion_date": "2034-10-11", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-09T02:05:33.993Z", "location_count": 108, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Chico, California + 91 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Chico", "state": "California" }, { "city": "Encinitas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06632977" }, { "nct_id": "NCT04703192", "title": "Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed/Refractory Peripheral T-Cell Lymphoma", "Adult T Cell Leukemia/Lymphoma" ], "interventions": [ { "name": "Valemetostat Tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2021-06-03", "completion_date": "2027-08-31", "has_results": true, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-09-09T02:05:33.993Z", "location_count": 14, "location_summary": "Duarte, California • Palo Alto, California • San Francisco, California + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04703192" }, { "nct_id": "NCT06644768", "title": "A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Lung Cancer" ], "interventions": [ { "name": "valemetostat tosylate", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 137, "start_date": "2024-10-30", "completion_date": "2030-04-30", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-09-09T02:05:33.993Z", "location_count": 11, "location_summary": "La Jolla, California • Los Angeles, California • Jacksonville, Florida + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06644768" }, { "nct_id": "NCT05683171", "title": "A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Valemetostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2023-05-19", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-09-09T02:05:33.993Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05683171" }, { "nct_id": "NCT05633979", "title": "Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Valemetostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2023-02-09", "completion_date": "2032-12-31", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-09-09T02:05:33.993Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05633979" }, { "nct_id": "NCT05879484", "title": "Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sinonasal Cancer", "Squamous Non-small Cell Lung Cancer", "Lung Cancer", "Head and Neck Squamous Cell Carcinoma", "Head and Neck Carcnimona", "Head and Neck Cancer" ], "interventions": [ { "name": "pembrolizumab", "type": "DRUG" }, { "name": "valemetostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 0, "start_date": "2025-07-09", "completion_date": "2025-07-09", "has_results": false, "last_update_posted_date": "2025-07-10", "last_synced_at": "2026-09-09T02:05:33.993Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05879484" }, { "nct_id": "NCT06807632", "title": "A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Extensive-stage Small-cell Lung Cancer" ], "interventions": [ { "name": "Valemetostat", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2025-01-29", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-09T02:05:33.993Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06807632" } ] }